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ABSTRACT
Objective: More than 50% of patients with knee osteoarthritis (OA) had an inadequate pain relief in its management. Combination therapy could be 
the solution to this problem. The aim of this study was to compare the efficacy of combination therapy of diacerein and meloxicam with meloxicam 
alone in the patient with knee OA.
Methods: A total of 64 knee OA patients were recruited from Rumah Sakit Umum Daerah Dr. Mohammad Soewandhie Surabaya. They were allocated 
to combination group and single therapy group using randomized controlled trial design. The Western Ontario and McMaster Universities Arthritis 
Index (WOMAC) physical function questionnaire were assessed in weeks 0–4th. The difference between pre- and post-treatment score and area under 
the curve (AUC) of WOMAC score were calculated.
Results: Combination therapy and single therapy had significant clinical effect with the downregulated score of WOMAC physical function after 
4th week (p<0.05). However, there were no differences in AUC of WOMAC physical function score between combination and single therapy.
Conclusion: Patient with knee OA could gain beneficial efficacies from combination therapy of diacerein and meloxicam. Studies of longer follow-up 
time to get the differences in AUC of WOMAC physical function score are needed.
Keywords: Osteoarthritis, Diacerein, Meloxicam, Western Ontario and McMaster Universities Arthritis Index, Physical function.
INTRODUCTION
Osteoarthritis (OA) of the knee is a major cause of pain and locomotor 
disability worldwide [1]. Based on the World Health Organization 
data, OA is one of the ten most diseases that caused disability in 
developed countries. In Indonesia, there were 15.5% men and 12.7% 
women between 40 and 60 years who had a radiological knee OA [2].
Muscle weakness, especially of the quadriceps muscle, is one of the 
major musculoskeletal repercussions of knee OA [3]. As the quadricep 
muscle acts as a shock absorber in the knee joint, its weakness is 
believed to reduce functional capacity, predisposing the knee to 
structural damage [4]. OA and pain symptom experienced by patients 
have bad effects, such as walking limitations and limitations to 
work  [5,6]. However, more than 50% of patients with knee OA had an 
inadequate pain relief in its management [7-9].
OA is a complex process, so the combination of drugs that work by 
different mechanism may lead to a synergistic effect and can overcome 
the pain and progression of the disease [10-12]. A combination drug 
that can be offered to overcome bad physical function of the patient 
with OA is diacerein and meloxicam.
Diacerein is an interleukin 1 inhibitor that has efficacy in terms of 
functional manifestations and structural components of OA [13-15]. 
It plays an important role in cartilage degradation and stimulation 
of nociceptive pathways [16]. Diacerein had slow-acting properties, 
so it must be combined with other analgesics, such as nonsteroidal 
anti-inflammatory drugs (NSAIDs) to make a faster response in OA 
therapy [14,17]. Meloxicam showed benefit in pain management of knee 
OA and had a relatively safe profile. For OA pain therapy, meloxicam 
should only be used once daily [18-20].
The high prevalence of knee OA and its impact on the function and quality 
of life shows the importance of developing strategies for the treatment 
of that clinical condition. This study aimed at assessing the effect of 
combination therapy of diacerein and meloxicam and meloxicam alone on 
the physical function of patients with knee OA. The Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) score was widely used as 
a tool to assess the physical function of the patient with arthritis [21,22].
METHODS
Study design
We designed an open-label, randomized control trial study. The trial 
was approved by Badan Koordinasi Pendidikan Rumah Sakit Umum 
Daerah (RSUD) Dr. Mohammad Soewandhie Surabaya with approval 
number 070/2554/436.7.8/2016. We used a consecutive sampling 
method to get participant.
After 5 times of drug elimination half-life of pain medication previously 
consumed, the patient experienced pain at least 24 h with scale ≥4 
was randomized with blocked randomization method. If patients 
experienced sudden pain during the washout period, they would be 
given rescue medication (paracetamol 500 mg, maximum 4 g/day).
Participants received either the combination of diacerein (Artoflam®) 
50 mg once daily and meloxicam 15 mg once daily or meloxicam 15 mg 
once daily for 4 weeks. Patients were followed up every week. Patients 
who missed more than 20% of the drugs were taken out of the study. 
Other criteria to drop out the participant was incident of severe adverse 
effect and violation of study protocol.
Patient
Patients were eligible to participate in the study if they had a knee OA 
confirmed by orthopedic spesialist, had radiographic finding consistent 
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with the disease, 18–75 years old, body mass index (BMI) ≤39 kg/m2, 
and had moderate pain when they did not use analgesic (pain score ≥4 
with 0–10 scale). The patient could be included in our study if had a knee 
OA based on Indonesian Rheumatism Association criteria [2]. Informed 
consent was obtained from all participants. Patients were recruited 
from outpatients of the orthopedy clinic in RSUD Dr. Mohammad 
Soewandhie Surabaya.
Patient with malignancy; pregnant or using hormonal contraceptive; 
psychiatric disorders using antidepressants, anticonvulsants, 
antipsychotics, sedatives, or muscle relaxant; drug dependency, drug 
abuse, or alcohol abuse; hypertension with diastolic >95 or systolic 
>165), heart failure, or unstable angina; liver and kidney disorder 
(creatinine clearance ≤30 ml/min that was calculated with Cockroft–
Gault formula); bleeding disorder or using anticoagulant or aspirin 
with daily dose more than 325 mg; and history of allergy with drug used 
in this study were excluded from the study.
Evaluation of physical function outcome
Physical function was measured by the WOMAC physical function 
questionnaire that was translated into Bahasa Indonesia and was 
validated in our study. The WOMAC physical function score was 
assessed at baseline and every week until the 4th week. The area under 
the curve (AUC) of the WOMAC physical function score on each subject 
was calculated up to 4 weeks of observation using the trapezoidal rule.
Statistical analysis
The validity of WOMAC physical function test was analyzed with Pearson 
correlation procedure, and reliability was analyzed with Cronbach’s 
alpha value. Descriptive and inferential statistics were calculated for 
baseline characteristics. The score of WOMAC physical function was 
analyzed with per protocol method. Normality of the data was tested 
with a Shapiro–Wilk test and homogeneity of the data was tested with 
Levene’s test. Paired sample t-test or Wilcoxon signed-rank test was 
used to determine whether pre-treatment and post-treatment groups 
differed. Independent samples t-test or Mann–Whitney U-test was used 
to determine the difference between the combination of diacerein and 
meloxicam and meloxicam alone groups. For all tests, data between 
different groups were significant if p<0.05.
RESULTS
A total of 68 subjects were participated (34 subjects per group). 
Approximately 62 (91.2%) patients completed the study and included 
in the analysis (Fig. 1.) The two treatment groups were similar with 
regard to baseline characteristic (Table 1).
WOMAC physical function evaluation
The WOMAC physical function score decreased significantly in all 
groups when compared to the baseline values of each group (p < 0.05) 
after 4-week therapies (Table 2).
In the 1st week until 3rd week, the difference of WOMAC physical 
function score between the combination of meloxicam and diacerein 
and meloxicam alone could not be seen. Those differences were seen 
Table 1: Baseline characteristics
No Patients characteristics Combination of diacerein and meloxicam Meloxicam alone p
Gender
1 Female Σ (%) 24 (80.0) 25 (78.1) 1.000
Male Σ (%) 6 (20.0) 7 (21.9)
Age (years)
2 ≥60 16 (53.3) 18 (56.3) 1.000
<60 14 (46.7) 14 (43.8)
Mean±SD (year) 61.13±8.53 60.41±7.69 0.860
BMI
3 Normal weight Σ (%) 11 (36.7) 6 (18.8) 0.136
Overweight Σ (%) 13 (43.4) 13 (40.6)
Obese Σ (%) 6 (20.0) 13 (40.6)
WOMAC physical function score
4 Mean±SD 31.70±11.74 34.34±10.15 0.346
Menopausal status
5 Menopause Σ (%) 20 (83.3) 24 (96.0) 0.189
Not menopause Σ (%) 4 (16.7) 1 (4.0)
OA grade
6 1 Σ (%) 2 (6.67) 0 (0.0) 0.212
2 Σ (%) 8 (26.7) 19 (59.4)
3 Σ (%) 16 (53.3) 8 (25.0)
4 Σ (%) 4 (13.3) 5 (15.6)
Duration of OA (years)
7 ≥5 Σ (%) 2 (6.7) 1 (3.1) 0.607
<5 Σ (%) 28 (93.3) 31 (96.9)
mean±SD (years) 1.13±1.80 0.75±1.92 0.089
Involved joints
8 Unilateral 15 (50.0) 12 (37.5) 0.462
Bilateral 15 (50.0) 20 (62.5)
BMI: Body mass index (normal weight≥18 kg/m2 and <25 kg/m2; overweight ≥25 kg/m2 and <30 kg/m2; obese ≥30 kg/m2). WOMAC: The Western Ontario and 
McMaster Universities Arthritis Index, OA: Osteoarthritis, Sample size: Combination group=30; meloxicam alone group=32
Fig. 1: Participant flow diagram
327
Asian J Pharm Clin Res, Vol 11, Issue 10, 2018, 325-329
 Dwicandra and Jaya 
at 4th week (p<0.05). There was no significant difference in AUC and 
improvement of WOMAC physical function score (Table 3).
DISCUSSIONS
This study showed that a combination of diacerein (50 mg/day) 
and meloxicam (15 mg/day) or meloxicam alone (15 mg/day) had a 
statistically significant analgesic effect (pre- and post-treatment). The 
effectiveness of meloxicam on the outcome WOMAC physical function 
score was supported by the randomized controlled trial study by Yocum 
et al. in the knee and hip OA. It was found that there were differences 
in WOMAC score of physical function in pre- and post-treatment after 
2 weeks of meloxicam (15 mg/day) therapy [18].
In our study, the combination of diacerein and meloxicam was also 
effective to reduce the WOMAC physical function score after 4 weeks 
of therapy. There were no studies that compare the combined effects 
of diacerein and meloxicam. However, there were similar studies 
conducted by Gupta et al. In the study, diacerein 50 mg administration 
combined with other NSAID diclofenac 75 mg/d (N=25) was shown 
a significant difference in WOMAC physical function score than 
baseline score after 12 weeks of therapy. That study did not explain 
the differences in pain scores over time compared to baseline. That 
study only compared the differences in WOMAC score in pre and post-
treatment [23]. However, the significant WOMAC score reduction after 
4 weeks of observation was supported by the results of the literature 
study, which diacerein effect occurs 2–4 weeks after therapy, and was 
significant after 4–8 weeks [24]. Meloxicam achieves a significant 
analgesic effect in 2–4 week [20].
There was a different result of this study and a study conducted by 
Gupta et al. In our study, the analgesic effect appeared in the 4th week. 
The difference in the timing of the analgesic effect on the WOMAC score 
in the literature study and our study may be due to the difference in 
comparators used. In addition, the differences may also be due to the 
different follow-up times between our study and the literature.
When we compared with meloxicam alone, the combination of diacerein 
and meloxicam showed a significant difference in WOMAC physical 
function score at 4th week. This result indicated that a combination of 
diacerein and meloxicam was superior to meloxicam alone. In a study 
conducted by Gupta et al., which compared the combination of diacerein 
50 mg/day and diclofenac 75 mg/day with diclofenac 150 mg/day, the 
WOMAC physical function score difference appeared at 16th week [23]. 
This result was longer than our study. The differences in the participant 
characteristic may be responsible for this effect. In another study, 
meloxicam showed the same effectiveness in overcoming OA pain 
compared to diclofenac [25].
Pain responses between different participant characteristic may also 
vary, so participant’s factor greatly influences the results of our study. 
The onset of therapy between Gupta et al. study and this study was 
different. In Gupta study, the analgesic effect did not appear immediately 
in early week. Gupta et al. used a different dose of diclofenac in single 
group and combination group. It may be responsible for delay onset of 
analgesic effect.
When comparisons were made using the difference and AUC of 
WOMAC physical function score, the combination of diacerein and 
meloxicam showed no significant difference. Area under curve data 
are the result of combining WOMAC score over time calculated using 
trapezoidal rules. The WOMAC score can be transformed into AUC to 
access the benefits of analgesia [26]. Compared with measurements at 
the end of study (EOS), the trial results using AUC provide a smaller 
treatment estimate but with better precision. The AUC value provides 
the possibility to maintain the treatment group differences by taking 
into account the precise onset and offset of drug action. In the COBRA 
trial with rapid-acting drugs, AUC is more sensitive than EOS to detect 
treatment differences [27]. The AUC analysis is also more stable and 
sensitive to interpatient differences than other measures [28]. The 
AUC describes the cumulative response of an intervention but does not 
provide information on the onset of analgesic effects. For additional 
information on the onset of the onset therapy, we used AUC and 1st–4th-
week score.
When we compared WOMAC score difference parameters (pre- and 
post-treatment score) and AUC of WOMAC scores, the combination 
of diacerein and meloxicam did not show significant differences with 
meloxicam alone. This suggests that, overall, there was no significant 
difference in WOMAC outcomes of physical function between diacerein 
and meloxicam combination groups compared to meloxicam alone. 
Most studies used the measurement of endpoint study results to see 
the comparison of therapy outcomes. In a study conducted by Gupta 
(2012), no comparison of AUC values of WOMAC sore was observed 
in the combination group diacerein and diclofenac as well as a single 
diclofenac group [23].
Table 2: Comparison of WOMAC physical function score between pre‑ and post‑treatment in intervention groups
No Groups WOMAC physical function score Mean±SD Sig
1 Combination of diacerein and meloxicam Pre-treatment 31.70±11.74 0.001*
Post-treatment 17.01±8.18
2 Meloxicam alone Pre-treatment 34.34±10.15 0.001*
Post-treatment 21.89±8.90
Sig: Significance, SD: Deviation standard. *p<0.05, Sample size: Combination group=30; Meloxicam alone group=32, WOMAC: The Western Ontario and McMaster 
Universities Arthritis Index
Table 3: Comparison of WOMAC physical function score between the combination of meloxicam and diacerein and meloxicam alone
No Time of follow‑up Combination of diacerein dan 
meloxicam
Meloxicam alone Sig
Mean±SD CI 95% Mean±SD CI 95%
1 Week 0 31.70±11.74 27.32–36.08 34.34±10.15 30.68–38.00 0.346
2 Week 1 26.67±12.13 22.14–31.20 29.72±9.82 26.18–33.26 0.279
3 Week 2 24.17±11.31 19.94–28.39 28.06±10.08 24.43–31.70 0.157
4 Week 3 20.67±9.99 16.93–24.40 24.69±9.77 21.17–28.21 0.140
5 Week 4 17.07±8.17 14.01–20.12 21.81±8.90 18.60–25.02 0.033*
6 AUC 95.88±41.10 80.54-111.23 110.55±37.60 96.99–124.10 0.148
7 Improvement 14.63±9.095 11.24–18.03 12.53±6.76 10.09–14.97 0.577
SD: Standard deviation, CI 95%: Confident interval 95%, Sig: Significance, *p<0.05, AUC: Area under curve, Sample size: Combination group=30; meloxicam alone 
group=32
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The difference in WOMAC physical function data was not used as the 
main outcome to show the effectiveness of the therapy. It was feared 
that although at the beginning of the observation there was a decrease 
in WOMAC physical function score, there was a possibility that the score 
would again increase to a baseline score or a larger score at the end of 
the observation. This may cause an unexpected analgesic effect in the 
midst of observation. The WOMAC physical function score difference 
showed no significant differences. Hence, it was concluded that, after 
4 weeks of therapy, there was no significant improvement in the 
WOMAC physical function score outcome between the combination and 
single groups.
Other studies support the non-significant outcome differences in 
WOMAC physical function scores between the combination of diacerein 
and meloxicam with meloxicam alone. In our study, the addition of 
diacerein to meloxicam did not make a significant difference compared 
to meloxicam alone after 4 weeks of therapy. Meta-analysis and 
systematic review by Kongtharvonskul et al. showed that diacerein did 
not clinically significantly reduced the WOMAC function physical (from 
8 studies, p=0.392) than placebo (follow-up time of 12–16 week , and 
doses of 50–100 mg/day) [29].
Another study conducted by Gupta et al. showed a significant difference 
of WOMAC physical function (16th week of follow-up) between the 
combination of diacerein 50 mg and NSAIDs (Diclofenac 75 mg/day) 
compared with diclofenac alone. That means we need longer follow-
up to be able to see the difference of WOMAC physical function score 
between combination effect of diacerein and meloxicam compared to 
meloxicam alone [29].
Another study conducted by Singh et al. also saw a comparison of the 
addition of NSAIDs (diclofenac) to diacerein therapy. The study was 
conducted for 3 month. The combined group (N=37) used diacerein 
50 mg/day in the 1st month, 2×50 mg/day at 2nd and 3rd months, 
and diclofenac 75 mg/d sustained release from 1st to 3rd weeks. The 
comparison group (N=37) only used diclofenac 75 mg/day in sustained 
release form. The effectiveness of therapy was seen from the total 
WOMAC score. After 3 months of therapy, the combination group gave 
a better outcome (WOMAC 15.9±2.40) than diclofenac alone (WOMAC 
36.8±2.92) with a significance value of p<0.05. Thus, for 3 months 
of therapy, diacerein administration on diclofenac gave a significant 
difference in WOMAC score compared to diclofenac alone [30]. The 
above differences also appeared for a longer period (3 month) than our 
study. The study did not explain the difference between WOMAC scores 
over time, so it is not known when the differences began to appear. If 
we assumed the differences occurred in the 3rd month (12th week), it 
would take longer observation time from this study to be able to see 
differences in the effect of diacerein and meloxicam combination 
compared to single meloxicam in OA patients in WOMAC outcome. In 
addition, the study used a multilevel dose (50 mg/day diacerein in the 
1st month, followed by 100 mg/day for the next 2 months). These dose 
differences may also affect the differences in WOMAC outcome.
When referring to the differences in WOMAC score that appears at 4th 
week, we can said that combination of diacerein and meloxicam was 
potential to provide benefits in OA therapy. This is also supported by a 
literature study showing that diacerein effects begin to appear at 2nd and 
4th weeks and significant at 4th to 8th week [14]. Thus, intervention up 
to 8th w is required to see the differences of AUC of WOMAC physical 
function score to find the benefits of this combination.
Difference in baseline characteristics can also influence the different 
results of our study. These factors include gender factors, BMI, duration 
of OA, education level, and the number of joints with OA. There was a 
difference in the proportion of men and women in studies conducted 
by Gupta et al. compared to our study [23]. In our study, sexes were 
dominated by women (78.1–80.0%), whereas in studies conducted 
by Gupta et al., the proportion between sexes of men and women was 
comparable (male:female = 2:3). Gender was known affecting WOMAC 
score. A study conducted by Elboim-Gabyzon et al. in 11 men and 52 
women showed that sex can provide significant differences in WOMAC 
physical function (p=0.004). Women had WOMAC values greater than 
men [31]. Research conducted by Elbaz et al using 1487 patient with 
symptomatic knee OA showed that BMI had a significant relationship 
with WOMAC physical function (p<0.001) [32]. A study of 105 elderly 
patients (≥60 years) with OA showed that women had worse conditions 
in WOMAC physical function (p=0.018) [33].
However, these studies and Gupta et al. study had a similar BMI 
category (overweight category), so BMI might not be a factor that made 
a different outcome.
Duration of OA also had a correlation with WOMAC score or other 
quality of life parameters. The study by Elstaar (2015), with 116 OA 
patients, found  that patients with a duration of  OA ≥5 years and <5 
years had a significant difference in the quality of life (p 0.008) [34].
The level of education had a relationship with the WOMAC score. A study 
conducted by Kulcu et al. on knee OA patients showed that there were 
inverse correlations of educational level with WOMAC physical function 
(r=−0.352; p=0.003) [35]. The number of joints involved in OA also had 
a correlation with the WOMAC score. Research by Riddle et al. states 
that the number of joints involved (unilateral or bilateral) provides 
significant differences in WOMAC scores, in which bilateral OA scores 
larger WOMACs [36]. The study by Gupta et al. was not mentioned 
about duration characteristics, educational level, and the number of 
joints involved in OA. Therefore, we could not compare Gupta studies 
with our study [23].
CONCLUSIONS
The combination of diacerein and meloxicam provided better physical 
function outcome than meloxicam alone. This significant effect was 
occurred at 4th week. Longer follows-up time to get the differences in 
AUC of WOMAC physical function score are needed.
ACKNOWLEDGMENT
The authors thank all of the subjects for participating in this study. 
We also acknowledge to orthopedic specialists in the Orthopedic 
Department of RSUD Dr. Mohammad Soewandhie Surabaya (Dr. Bimo 
Sasono, Dr. Carlos Supriyantono Binti, Sp.OT, and Dr. Gede Chandra 
Purnama Yudha, Sp.OT.) that helped the author during data collecting.
AUTHOR’S CONTRIBUTIONS
Author, Ni Made Oka Dwicandra, made substantial contributions 
to conception and design, acquisition of data, and analysis and 
interpretation of data. Co-author, Made Krisna Adi Jaya participated in 
data collecting, data analyzing, and drafting the article.
CONFLICTS OF INTEREST
All authors have declared no conflicts of interest.
REFERENCES
1. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, 
Arden NK, et al. OARSI recommendations for the management of 
hip and knee osteoarthritis: Part III: Changes in evidence following 
systematic cumulative update of research published through january 
2009. Osteoarthritis Cartilage 2010;18:476-99.
2. The Indonesian Rheumatism Association. Diagnosis dan 
Penatalaksanaan Osteoartritis. Jakarta: The Indonesian Rheumatism 
Association; 2014.
3. Petterson SC, Barrance P, Buchanan T, Binder-Macleod S, 
Snyder-Mackler L. Mechanisms underlying quadriceps weakness in 
knee osteoarthritis. Med Sci Sports Exerc 2008;40:422-7.
4. Fitzgerald GK, Piva SR, Irrgang JJ, Bouzubar F, Starz TW. Quadriceps 
activation failure as a moderator of the relationship between quadriceps 
strength and physical function in individuals with knee osteoarthritis. 
329
Asian J Pharm Clin Res, Vol 11, Issue 10, 2018, 325-329
 Dwicandra and Jaya 
Arthritis Rheum 2004;51:40-8.
5. Alldredge BK, Affairs A, Francisco S, Corelli RL, Ernst ME, City I, et al. 
Koda-Kimble and Young’s Applied Therapeutic: The Clinical Use of 
Drug. 10th ed. Philadelphia, PA: Lippincot Williams and Wilkins; 2013.
6.	 Łastowiecka	E,	Bugajska	J,	Najmiec	A,	Rell-Bakalarska	M,	Bownik	I,	
Jedryka-Góral A, et al. Occupational work and quality of life in 
osteoarthritis patients. Rheumatol Int 2006;27:131-9.
7. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, 
Mavros P, et al. Inadequate pain relief and large functional loss 
among patients with knee osteoarthritis: Evidence from a prospective 
multinational longitudinal study of osteoarthritis real-world therapies. 
Rheumatology (Oxford) 2015;54:270-7.
8. Jameson K, Balshaw R, Phillips C, Martin GR, Everett SV, Watson DJ, 
et al. PMS59 inadequate pain relief in knee osteoarthritis and patient 
reported outcomes: A survey of osteoarthritis real world therapies 
(SORT) in the United Kingdom. Int Soc Pharm Outcomes Res 
2011;14:A313.
9. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, 
Mavros P, et al. Inadequate pain relief and large functional loss 
among patients with knee osteoarthritis: Evidence from a prospective 
multinational longitudinal study of osteoarthritis real-world therapies. 
Rheumatology (Oxford) 2015;54:270-7.
10. Mercadante S, Casuccio A, Agnello A, Pumo S, Kargar J, Garofalo S, 
et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in 
cancer pain due to somatic or visceral mechanisms. J Pain Symptom 
Manage 1999;17:351-6.
11. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. 
Duloxetine added to oral nonsteroidal anti-inflammatory drugs for 
treatment of knee pain due to osteoarthritis: Results of a randomized, 
double-blind, placebo-controlled trial. Curr Med Res Opin 
2011;27:2361-72.
12. Ohtori S, Inoue G, Orita S, Takaso M, Eguchi Y, Ochiai N, et al. 
Efficacy of combination of meloxicam and pregabalin for pain in knee 
osteoarthritis. Yonsei Med J 2013;54:1253-8.
13. Fidelix T, Macedo C, Maxwell L, Fernandes Moça Trevisani V. 
Diacerein for osteoarthritis. Cochrane Database of Systematic Reviews; 
2014.
14. Medhi B. Diacerein: A new disease modulating agent in osteoarthritis. 
Int J Pharm Med Res 2007;18:48-52.
15. Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: A new 
symptomatic slow acting drug for osteoarthritis. JK Sci 2006;8:173-5.
16. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. 
A current review of molecular mechanisms regarding osteoarthritis and 
pain. Gene 2013;527:440-7.
17. Gayathri C, Vanitha S, William FJ, Nirmala P. Comparative analysis 
of efficacy and safety of diacerein versus S-Adenosyl methionine in 
the management of osteoarthritis of knee joint. Int J Curr Pharm Res 
2017;9:46-51.
18. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P, et al. 
Safety and efficacy of meloxicam in the treatment of osteoarthritis: 
A 12-week, double-blind, multiple-dose, placebo-controlled trial. 
The meloxicam osteoarthritis investigators. Arch Intern Med 
2000;160:2947-54.
19. Zeidler H, Kaltwasser JP, Leonard JP, Kohlmann T, Sigmund R, 
Degner F, et al. Prescription and tolerability of meloxicam in day-to-day 
practice: Postmarketing observational cohort study of 13,307 patients 
in Germany. J Clin Rheumatol 2002;8:305-15.
20. Tacca MD, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability 
of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory 
drug. Clin Drug Inves 2002;11:1-22.
21. Bellare N, Harshadargekar, Bhagwat A, Situt V, Pandita N. Effect of a 
combination of glucosamine and chondroitin sulphate supplementation 
on the symptomatic relief observed in indian patients with knee 
osteoarthritis. Int J Pharm Pharm Sci 2013;5:647-50.
22. Patwardhan S, Bodas K, Gundewar S. Coping with arthritis using safer 
herbal options. Int J Pharm Pharm Sci 2010;2:1-11.
23. Gupta N, Datta S. Efficacy and safety of diacerein and diclofenac in 
knee osteoarthritis in Indian patients-a prospective randomized open 
label study. J Biomed Sci 2012;1:1-14.
24. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, 
et al. Efficacy and safety of diacerein in osteoarthritis of the knee: 
A double-blind, placebo-controlled trial. The diacerein study group. 
Arthritis Rheum 2000;43:2339-48.
25. Goei Thè HS, Lund B, Distel MR, Bluhmki E. A double-blind, 
randomized trial to compare meloxicam 15 mg with diclofenac 100 mg 
in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 
1997;5:283-8.
26. Lee CJ, Lee LH, Wu CL, Lee BR, Chen M-L. Clinical Trials of Drug 
and Biopharmaceuticals. USA: Taylor and Francis Group; 2006.
27. Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P, 
et al. Validity of area-under-the-curve analysis to summarize effect in 
rheumatoid arthritis clinical trials. J Rheumatol 1999;26:712-6.
28. Schiff M. A rationale for the use of summary measurements for the 
assessment of the effects of rheumatoid arthritis therapies. Clin Ther 
2003;25:993-1001.
29. Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, 
Woratanarat P, Thakkinstian A, et al. Efficacy and safety of glucosamine, 
diacerein, and NSAIDs in osteoarthritis knee: A systematic review and 
network meta-analysis. Eur J Med Res 2015;20:24.
30. Tonelli SM, Rakel BA, Cooper NA, Angstom WL, Sluka KA. Women 
with knee osteoarthritis have more pain and poorer function than men, 
but similar physical activity prior to total knee replacement. Biol Sex 
Differ 2011;2:12.
31. Elboim-Gabyzon M, Rozen N, Laufer Y. Gender differences in pain 
perception and functional ability in subjects with knee osteoarthritis. 
ISRN Orthop 2012;2012:413105.
32. Elbaz A, Debbi E, Segal G, Haim A Halperin N, Agar G, Mor A, 
Debi R. Sex and Body Mass Index Correlate With Western Ontario and 
McMaster Universities Osteoarthritis Index and Quality of Life Scores 
in Knee Osteoarthritis. Arch Phys Med Rehabil 2011;92:1618-23.
33. Santos JP, Andraus RA, Pires-oliveira DA, Fernandes MT, Frâncica MC, 
Poli-frederico RC, et al. Analysis of functional status of elderly with 
osteoarthritis. Fisioter Pesq 2015;22:161-8.
34. Elstaar TE, Salama AA, Esaily HG, Bolty SA. Quality of life in patients 
with primary knee osteoarthritis. Menoufi Med J 2015;29:111-4.
35. Kulcu DG, Yanik B, Atalar H, Gulsen G. Associated factors with pain 
and disability in patients with knee osteoarthritis. Turk J Rheumatol 
2010;25:77-81.
36. Riddle DL, Stratford PW. Original article unilateral vs bilateral 
symptomatic knee osteoarthritis: Associations between pain intensity 
and function. Rheumatology 2013;52:2229-37.
